N/A
Completed N=385
Special Survey Long-term Treatment With Tiotropium on COPD
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT00638183 ↗
Enrolled (actual)
385
Serious AEs
8.9%
Results posted
Apr 2010
Primary outcomePrimary: Number of Patients With Adverse Events (AEs) — 71 Participants
Summary
Since Spiriva Inhalation Capsules 18mcg (hereinafter this product) are indicated for treatment of patients with chronic obstructive pulmonary disease (i.e. patients with chronic bronchitis or pulmonary emphysema) and usually intended for long-term use, the present survey is conducted to collect safety and effectiveness information on the use of this product for long period of time in daily clinical settings, and to obtain proper drug use information.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Adverse Events (AEs) |
71 | — |
| PRIMARY Number of Patients With Adverse Drug Reactions (ADRs) |
27 | — |
| SECONDARY Effective Rate of Comprehensive Evaluation |
70.9 | — |
| SECONDARY Change in Forced Expiratory Volume (L) in 1 Second at 52 Weeks |
0.119 | — |
Eligibility Criteria
Inclusion Criteria
- Patients of Chronic Obstructive Pulmonary Disease
- Patients were expected to use the product for long period of time
Exclusion Criteria
- Patients with glaucoma
- Patients with micturition disorder due to prostatic hyperplasia etc.
- Patients with a history of hypersensitivity to atropine or its derivatives or to any component of this product
Data sourced from ClinicalTrials.gov (NCT00638183). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.